Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT01172028 Completed - Breast Cancer Clinical Trials

Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

Start date: September 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors.

NCT ID: NCT01171898 Active, not recruiting - Prostate Cancer Clinical Trials

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Start date: July 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.

NCT ID: NCT01168479 Completed - Prostate Cancer Clinical Trials

FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

FLAME
Start date: September 2009
Phase: Phase 3
Study type: Interventional

Rationale: Dose escalation in external-beam irradiation has proven to benefit outcome in local prostate cancer. Randomized trials were performed up to doses of 78 Gy in 2 Gy fractions. Nevertheless, the five-year biochemical relapse rate still was approximately 35% in the high-dose arm. Therefore further dose escalation seems to be required. A feasibility study up to appr. 85 Gy on the entire prostate has already been performed and showed acceptable toxicity when combined with adequate position verification. Higher doses to the entire prostate are expected to increase severe toxicity. As local recurrences only occur at the site of the primary macroscopic tumour area the next step in increasing the dose should be an ablative boost to the macroscopic tumour alone, while electively irradiating the rest of the prostate to the current gold standard dose. Feasibility of this approach has been shown for an ablative dose of 95 Gy to the macroscopic tumour within the prostate.

NCT ID: NCT01168323 Completed - Prostate Cancer Clinical Trials

Spaced Education to Optimize Prostate Cancer Screening

Start date: January 2007
Phase: N/A
Study type: Interventional

Two memory research findings (the spacing and testing effects) can dramatically improve retention of learning, but they have largely have been ignored by educators. The researchers have developed a novel form of online education (termed 'spaced education') based on these two effects which has been shown in randomized trials to improve knowledge acquisition and boost learning retention. Using prostate cancer screening as an experimental system, the researchers investigated whether spaced education could durably improve clinicians' behaviors, not just their knowledge.

NCT ID: NCT01168141 Enrolling by invitation - Prostate Cancer Clinical Trials

Window Study of ZD4054 in Metastatic Prostate Cancer

Start date: July 2009
Phase: N/A
Study type: Interventional

This is a prospective study in which patients with castrate-resistant prostate cancer and bone metastases will undergo imaging, donate blood, bone marrow and urine samples, and where possible primary tumour and bone metastatic tissue, before and during treatment with ZD4054, an orally active specific endothelin-A antagonist. The samples will be used primarily for biomarker studies, and it is hypothesized that these will inform on the mechanism of action of this drug. Magnetic Resonance Imaging (MRI) will be performed to evaluate emerging functional imaging endpoints as markers of early response in bone metastatic prostate cancer.

NCT ID: NCT01163448 Withdrawn - Prostate Cancer Clinical Trials

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Start date: July 2010
Phase: Phase 1
Study type: Interventional

This study is being done to test the safety of a single high-dose of radiation therapy before radical prostatectomy (removal of the prostate). The investigators want to find out what effects, good and/or bad, the radiation will have on men undergoing prostatectomy. The investigators are especially interested in men who are at risk for having cancer cells that have spread outside the prostate.

NCT ID: NCT01162395 Completed - Prostate Cancer Clinical Trials

Open Label Prostate Cancer Study

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)

NCT ID: NCT01162135 Completed - Prostate Cancer Clinical Trials

Digoxin for Recurrent Prostate Cancer

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time).

NCT ID: NCT01161563 Completed - Prostate Cancer Clinical Trials

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

NCT ID: NCT01160705 Completed - Prostate Cancer Clinical Trials

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Start date: November 2009
Phase:
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying blood samples in predicting how patients with prostate cancer will respond to treatment with docetaxel.